Craig A. Mullen

9.9k total citations · 3 hit papers
80 papers, 6.7k citations indexed

About

Craig A. Mullen is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Craig A. Mullen has authored 80 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 30 papers in Immunology and 26 papers in Oncology. Recurrent topics in Craig A. Mullen's work include Hematopoietic Stem Cell Transplantation (20 papers), Virus-based gene therapy research (18 papers) and Immunotherapy and Immune Responses (17 papers). Craig A. Mullen is often cited by papers focused on Hematopoietic Stem Cell Transplantation (20 papers), Virus-based gene therapy research (18 papers) and Immunotherapy and Immune Responses (17 papers). Craig A. Mullen collaborates with scholars based in United States, Italy and Belgium. Craig A. Mullen's co-authors include R. Michael Blaese, Kenneth V. I. Rolston, James I. Ito, Jo‐Anne H. Young, John R. Wingard, Eric J. Bow, Michael Boeckh, Alison G. Freifeld, Kent A. Sepkowitz and Issam Raad and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Craig A. Mullen

77 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

2011 2.3k citations Craig A. Mullen et al. profile →
T Lymphocyte-Directed Gene Therapy for ADA ⁻ SCID: Initial Trial Results After 4 Years

1995 983 citations R. Michael Blaese, Craig A. Mullen et al. profile →
Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

2011 507 citations Craig A. Mullen et al. profile →

Peers

Countries citing papers authored by Craig A. Mullen

Since Specialization

Citations

This map shows the geographic impact of Craig A. Mullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig A. Mullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig A. Mullen more than expected).

Fields of papers citing papers by Craig A. Mullen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig A. Mullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig A. Mullen. The network helps show where Craig A. Mullen may publish in the future.

Co-authorship network of co-authors of Craig A. Mullen

This figure shows the co-authorship network connecting the top 25 collaborators of Craig A. Mullen. A scholar is included among the top collaborators of Craig A. Mullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig A. Mullen. Craig A. Mullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant 2021 ·Anticancer Research ·(unknown), Jeffrey R. Andolina, Brooks L. Rademacher, Thomas J. Fountaine, (unknown), (unknown), (unknown), (unknown), Craig A. Mullen	0
2	Patterns of Diagnosis and Misdiagnosis in Pediatric Cancer and Relationship to Survival 2016 ·Journal of Pediatric Hematology/Oncology ·Jing Chen, Craig A. Mullen	19
3	Acute Lymphoid Leukemia Cells with Greater Stem Cell Antigen-1 (Ly6a/Sca-1) Expression Exhibit Higher Levels of Metalloproteinase Activity and Are More Aggressive In Vivo 2014 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), Craig A. Mullen	3
4	Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects 2010 ·Leukemia Research ·Johan Jansson, (unknown), Igor Kuzin, Andrew Campbell, Craig A. Mullen	6
5	High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells 2008 ·Biology of Blood and Marrow Transplantation ·Faith Young, Andrew Campbell, (unknown), Johan Jansson, Pin-Yi Wang, Craig T. Jordan, Craig A. Mullen	5
6	Hematopoietic Stem Cell Recipients Do Not Develop Post-transplantation Immune Tolerance to Antigens Present on Minimal Residual Disease 2007 ·Biology of Blood and Marrow Transplantation ·(unknown), Joanne Shaw, (unknown), (unknown), Craig A. Mullen	4
7	Interferon-α after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma 2006 ·Bone Marrow Transplantation ·Dimitrios Petropoulos, Laura L. Worth, Craig A. Mullen, (unknown), Mary Choroszy, K. W. Chan	5
8	Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses 2005 ·Leukemia & lymphoma ·(unknown), Joanne Shaw, Shahram Mori, Cherylyn A. Savary, Craig A. Mullen	6
9	Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation 2004 ·Biology of Blood and Marrow Transplantation ·Hai T. Tran, Demetrios Petropoulos, Laura L. Worth, Craig A. Mullen, Timothy Madden, B Andersson, Mary Choroszy, John Nguyen, (unknown), Ka Wah Chan	50
10	Fludarabine and Once-Daily Intravenous Busulfan for Allogeneic Bone Marrow Transplantation for Chediak-Higashi Syndrome 2003 ·Journal of Pediatric Hematology/Oncology ·Nancy Gordon, Craig A. Mullen, Hai T. Tran, Laura L. Worth, (unknown), Ka Wah Chan	7
11	Influence of Tumor Vaccines on Graft Versus Tumor Activity and Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation 2002 ·Leukemia & lymphoma ·Craig A. Mullen	6
12	Treatment of leukemia relapse with recombinant granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) following unrelated umbilical cord blood transplant: Induction of graft‐vs.‐leukemia 2002 ·Pediatric Transplantation ·Laura L. Worth, Craig A. Mullen, Mary Choroszy, (unknown), Ka‐Wah Chan	2
13	Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia 2002 ·Supportive Care in Cancer ·Ülker Koçak, Kenneth Rolston, Craig A. Mullen	14
14	Which children with fever and neutropenia can be safely treated as outpatients? 2001 ·British Journal of Haematology ·Craig A. Mullen	31
15	Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer 2000 ·Cancer Gene Therapy ·Fabio Candotti, Riad Agbaria, Craig A. Mullen, Renaud Touraine, Jan Balzarini, David G. Johns, R. Michael Blaese	13
16	Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice 1999 ·International Journal of Cancer ·Shigeki Kuriyama, Masaji Kikukawa, Kazuhiro Masui, (unknown), T NAKATANI, (unknown), Hitoshi Yoshiji, Hiroshi Fukui, (unknown), Craig A. Mullen, Tadasu Tsujii	35
17	Ganciclovir Chemoablation of Herpes Thymidine Kinase Suicide Gene-Modified Tumors Produces Tumor Necrosis and Induces Systemic Immune Responses 1998 ·Human Gene Therapy ·Craig A. Mullen, Larry D. Anderson, Kendra V. Woods, Michiya Nishino, Demetrios Petropoulos	38
18	Metabolic suicide genes in gene therapy 1994 ·Pharmacology & Therapeutics ·Craig A. Mullen	79
19	Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity 1989 ·Cellular Immunology ·Craig A. Mullen, Donald A. Rowley, Hans Schreiber	12
20	Multiple cancers. Tumor burden permits the outgrowth of other cancers. 1985 ·The Journal of Experimental Medicine ·Craig A. Mullen, J L Urban, Carter Van Waes, Donald A. Rowley, Hans Schreiber	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact